Related Experiment Video

Updated: Dec 11, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

663

Nanotechnology-Based Targeting of mTOR Signaling in Cancer

Mee-Sup Yoon1

  • 1Department of Molecular Medicine, School of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Republic of Korea.

International Journal of Nanomedicine
|August 22, 2020
PubMed

Insights

Nanoparticle drug delivery systems are being developed to target cancer by modulating mammalian target of rapamycin (mTOR) signaling. These nano-therapeutics offer enhanced bioavailability and reduced side effects for cancer treatment.

Area of Science:

  • Oncology
  • Biotechnology
  • Nanomedicine

Background:

  • Mammalian target of rapamycin (mTOR) is a key regulator of cell growth and metabolism.
  • mTOR signaling is frequently dysregulated in various cancers, making it a significant therapeutic target.
  • Current mTOR inhibitors face challenges in bioavailability and side effects.

Purpose of the Study:

  • To review the molecular mechanisms of nanoparticle-based mTOR modulators.
  • To summarize the current development of mTOR inhibitors utilizing nanoparticles.
  • To highlight the potential of nano-therapeutics for cancer treatment.

Main Methods:

  • Literature review of nanoparticle-based mTOR modulators.
  • Analysis of molecular mechanisms of action.
  • Survey of current research and development in the field.

Main Results:

  • Nanoparticle drug delivery systems can modulate mTOR signaling pathways.
  • These systems offer controlled drug release, enhancing bioavailability.
  • Nanoparticle-based mTOR inhibitors show promise in targeting and treating cancers with reduced side effects.

Conclusions:

  • Nanoparticle-based mTOR modulators represent a promising approach for cancer therapy.
  • Further understanding of their biological function will drive the development of effective nano-therapeutics.
  • This strategy holds potential for improved cancer treatment outcomes.
Keywords:
RapaLinkscancermTOR kinase inhibitormammalian target of rapamycinnanoparticlesnanotechnologyrapalogs

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.1K